HOME
>
臨床医学：一般
>
雑誌
> 最新医学別冊　診断と治療のABC140　慢性閉塞性肺疾患（COPD）

最新医学別冊　診断と治療のABC140　慢性閉塞性肺疾患（COPD）

出版社：	最新医学社
発行日：	2018-11-01
分野：	臨床医学：一般 > 雑誌
ISSN：	03708241
雑誌名：	最新医学
特集：	慢性閉塞性肺疾患（COPD）
電子書籍版：	2018-11-01

書籍・雑誌

≪全国送料無料でお届け≫

品切れ

5,500 円(税込)

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

目次

特集　慢性閉塞性肺疾患（COPD)

序
眼で見るCOPD

第1章　概念・定義と疫学
　概念・定義：COPD at a glance
　疫学

第2章　病理・病態生理
　病理
　病態生理
　病因
　肺合併症
　全身併存症
　コラム：嚢胞性肺疾患

第3章　診断
　問診・理学所見
　肺機能検査所見
　画像所見
　鑑別診断の最終ゴールは
　コラム：COPDの治療戦略に役立つ運動負荷心肺機能検査

第4章　管理・治療
　安定期の管理目標とアルゴリズム
　禁煙療法と禁煙運動
　ワクチン
　薬剤の選択
　治療薬剤
　　１．気管支拡張薬
　　２．吸入ステロイド
　身体活動性維持・向上とその評価
　呼吸リハビリテーション
　栄養療法
　酸素療法・換気補助療法
　びまん性肺気腫に対する外科治療と気管支鏡下治療
　増悪期の管理
　ACOへの対応
　経過・予後
　COPDの医療経済
　コラム：在宅管理

第5章　ガイドライン
　ガイドライン

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章概念・定義と疫学

P.19 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会編 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン. 第5版. メディカルレビュー社, 東京, 2018.

2) Fukuchi Y, et al : Chronic obstructive pulmonary disease (COPD) in Japan : The Nippon COPD epidemiology (NICE) study. Respirology 9 : 458-465, 2004.

3) Takahashi T, et al : Underdiagnosis and undertreatment of COPD in primary care setting. Tespirology 8 : 504-508, 2003.

4) Lange P, et al : Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 373 : 111-122, 2015.

5) McGeachie MJ, et al : Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med 374 : 1842-1852, 2016.

6) Svanes C, et al : Early life origins of chronic obstructive pulmonary disease. Thorax 65 : 14-20, 2010.

7) de Marco R, et al : Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 183 : 891-897, 2011.

8) Salvi SS, et al : Chronic obstructive pulmonary disease in non-smokers. Lancet 374 : 733-743, 2009.

9) Minakata Y, et al : Reduced level of physical activity in Japanese patients with chronic obstructive pulmonary disease. Respir Investg 52 : 41-48, 2014.

10) Handschin C, et al : The role of exercise and PGC1α in inflammation and chronic disease. Nature 454 : 463-469, 2008.

P.26 掲載の参考文献

1) 柴田陽光 : 特集COPD最新情報Topics 1疫学の動向と将来の予測. 日呼吸会誌 3 : 316-322, 2014.

2) Menezes AM, et al : Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study) : a prevalence study. Lancet 366 : 1875-1881, 2005.

3) Buist AS, et al : International variation in the prevalence of COPD (the BOLD Study) : a population-based prevalence study. Lancet 370 : 741-750, 2007.

4) Fukuchi Y, et al : COPD in Japan : the Nippon COPD Epidemiology study. Respirology 9 : 458-465, 2004.

5) Osaka D, et al : Relationship between habit of cigarette smoking and airflow limitation in healthy Japanese individuals : the Takahata study. Intern Med 49 : 1489-1499, 2010.

6) Matsumoto K, et al : Prevalence of asthma with airflow limitation, COPD, and COPD with variable airflow limitation in older subjects in a general Japanese population : the Hisayama Study. Respir Investig 53 : 22-29, 2015.

7) Muro S, et al : Relationship Among Chlamydia and Mycoplasma Pneumoniae Seropositivity, IKZF1 Genotype and Chronic Obstructive Pulmonary Disease in A General Japanese Population : The Nagahama Study. Medicine (Baltimore) 95 : e3371, 2016.

8) Yoshikawa M, et al : Prevalence of chronic obstructive pulmonary disease in independent community-dwelling older adults : The Fujiwara-kyo study. Geriatr Gerontol Int 17 : 2421-2426, 2017.

9) Kohansal R, et al : The natural history of chronic airflow obstruction revisited : an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 180 : 3-10, 2009.

10) Rycroft CE, et al : Epidemiology of chronic obstructive pulmonary disease : a literature review. Int J Chron Obstruct Pulmon Dis 7 : 457-494, 2012.

11) Kojima S, et al : Incidence of chronic obstructive pulmonary disease, and the relationship between age and smoking in a Japanese population. J Epidemiol 17 : 54-60, 2007.

12) Sato K, et al : Impact of cigarette smoking on decline in forced expiratory volume in 1s relative to severity of airflow obstuction in a Japanese general population : The Yamagata-Takahata study. Respir Investig 56 : 120-127, 2018.

13) 日本呼吸器学会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版第1章疾患概念と基礎知識 B. 疫学と経済的・社会的負荷. メディカルレビュー社, 東京, 2018.

14) Shibata Y, et al : A lower level of forced expiratory volume in 1 second is a risk factor for all-cause and cardiovascular mortality in a Japanese population : the takahata study. PLoS One 8 : e83725, 2013.

第2章病理・病態生理

P.32 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD診断と治療のためのガイドライン 2018. 2018.

2) Nagai A, et al : The National Institutes of Health Intermittent Positive-Pressure Breathing trial : pathology studies. II. Correlation between morphologic findings, clinical findings, and evidence of expiratory airflow obstruction. Am Rev Respir Dis 132 : 946-953, 1985.

3) Hogg JC, et al : Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 278 : 1355-1360, 1968.

4) McDonough JE, et al : Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365 : 1567-1575, 2011.

5) The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis 132 : 182-185, 1985.

6) Wright JL, et al : Pulmonary hypertension in chronic obstructive pulmonary disease : current theories of pathogenesis and their implications for treatment Thorax 60 : 605-609, 2005.

7) Hogg JC, et al : The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 : 2645-2653, 2004.

8) Saetta M, et al : CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 : 822-826, 1998.

9) Barnes PJ : Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 138 : 16-27, 2016.

10) Caramori G, et al : COPD immunopathology. Semin Immunopathol 38 : 497-515, 2016.

11) Thomsen M, et al : Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186 : 982-988, 2012.

12) Tsantikos E, et al : Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease. J Clin Invest 129 : 2406-2418, 2018.

13) Lange P, et al : Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 373 : 111-122, 2015.

P.39 掲載の参考文献

1) Hogg JC, et al : The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 : 2645-2653, 2004.

2) O'Donnell DE, et al : Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 148 : 1351-1357, 1993.

3) O'Donnell DE, et al : Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmpnary disease. Am J Respir Crit Care Med 164 : 770-777, 2001.

4) O'Donnell DE, et al : Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 : 832-840, 2004.

5) O'Donnell DE, et al : Exertional dyspnoea in COPD : the clinical utility of cardiopulmonary exercise testing. Eur Respir Rev 25 : 333-347, 2016.

6) Burgel PR, et al : Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J 32 : 1068-1081, 2008.

7) Miotto D, et al : Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. Eur Respir J 22 : 602-608, 2003.

8) Rahman I : Oxidative stress in pathogenesis of chronic obstructive pulmonary disease : cellular and molecular mechanisms. Cell Biochem Biophys 43 : 167-188, 2005.

9) West JB : Obstructive Diseases. Pulmonary Pathophysiology : The Essentials (PULMONARY PATHOPHYSIOLOGY (WEST) (West JB, ed)). p47-73. Lippincott Williams & Wilkins, Philadelphia, 2012.

10) Wagner PD, et al : Vendiation-perfusion inequality in chronic pulmonary disease. J Clin Invest 59 : 203-216, 1977.

11) Kubo K, et al : Effects of lung volume reduction surgery on exercise pulmonary hemodynamics in severe emphysema. Chest 114 : 1575-1582, 1998.

12) Chaouat A, et al : Pulmonary hypertension in COPD. Eur Respir J 32 : 1371-1385, 2008.

13) Arao T, et al : In vivo evidence of endothelial injury in chronic obstructive pulmonary disease by lung scintigraphic assessment of 123I-metaiodobenzylguanidine. J Nucl Med 44 : 1747-1754, 2003.

14) Wells JM, et al : Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 367 : 913-921, 2012.

15) Hurdman J, et al : Pulmonary hypertension in COPD : results from the ASPIRE registry. Eur Respir J 41 : 1292-1301, 2013.

P.49 掲載の参考文献

1) 日本呼吸器学会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. 日本呼吸器学会, 東京, 2018.

2) Postma DS, et al : Risk factors and early origins of chronic obstructive pulmonary disease. Lancet 385 : 899-909, 2015.

3) Eisner MD, et al : An official American Thoracic Society public policy statement : novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182 : 693-718, 2010.

4) Lamprecht B, et al : COPD in never smokers : results from the population-based Burden of Obstructive Lung Disease study. Chest 139 : 752-763, 2011.

5) Salvi SS, et al : Chronic obstructive pulmonary disease in non-smokers. Lancet 374 : 733-743, 2009.

6) 厚生労働省 : 喫煙と健康喫煙の健康影響に関する検討会報告書 <http://www.mhlw.go.jp/stf/shingi2/0000135586.html>

7) 佐々木治一郎 : タバコ煙の成分と疾患発症メカニズム. 日臨 71 : 383-389, 2013.

8) Jayes L, et al : Systematic reviews and meta-analyses of the effects of smoking on respiratory health. Chest 150 : 164-179, 2016.

9) Kohansal R, et al : The natural history of chronic airflow obstruction revisited : an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 180 : 3-10, 2009.

10) Scanlon PD, et al : Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161 : 381-390, 2000.

11) Josephs L, et al : Improved outcomes in ex-smokers with COPD : a UK primary care observational cohort study. Eur Respir J 49 : 1602114, 2017.

12) Ukawa S, et al : Passive smoking and chronic obstructive pulmonary disease mortality : findings from the Japan collaborative cohort study. Int J Public Health 62 : 489-494, 2017.

13) Savran O, et al : Early life insults as determinants of chronic obstructive pulmonary disease in adult life. Int J Chron Obstruct Pulmon Dis 13 : 683-693, 2018.

14) Guerra S, et al : Combined effects of parental and active smoking on early lung function deficits : a prospective study from birth to age 26 years. Thorax 68 : 1021-1028, 2013.

15) Sadhra S, et al : Occupational COPD and job exposure matrices : asystematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 12 : 725-734, 2017.

16) Lytras T, et al : Occupational exposures and 20-year incidence of COPD : the European Community Respiratory Health Survey. Thorax 2018 [Epub ahead of print].

17) Kurmi OP, et al : COPD and chronic bronchitis risk of indoor air pollution from solid fuel : a systematic review and meta-analysis. Thorax 65 : 221-228, 2010.

18) Hu G, et al : Risk of COPD from exposure to biomass smoke : a metaanalysis. Chest 138 : 20-31, 2010.

19) Siddharthan T, et al : Association between house-hold air pollution exposure and chronic obstructive pulmonary disease outcomes in 13 low-and middle-income country settings. Am J Respir Crit Care Med 197 : 611-620, 2017.

20) Amaral AFS, et al : Airflow obstruction and use of solid fuels for cooking or heating : BOLD results. Am J Respir Crit Care Med 197 : 595-610, 2017.

21) 環境省 : 粒子状物質 (PM2.5) に関する情報. <https://www.env.go.jp/air/osen/pm/infb.html> (2018)

22) Li MH, et al : Short-term exposure to ambient fine particulate matter increases hospitalizations and mortality in COPD : a systematic review and meta-analysis. Chest 149 : 447-458, 2016.

23) Aldrich TK, et al : Lung function trajectories in World Trade Center-exposed New York City firefighters over 13 years : The roles of smoking and smoking cessation. Chest 149 : 1419-1427, 2016.

24) Singh A, et al : Predictors of asthma/COPD overlap in FDNY firefighters with World Trade Center dust exposure : a longitudinal study. Chest 2018 [Epub ahead of print].

25) Andersen Z et al : Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution : a cohort study. Am J Respir Crit Care Med 183 : 455-461, 2011.

26) Schikowski T, et al : Association of ambient air pollution with the prevalence and incidence of COPD. Eur Respir J 44 : 614-626, 2014.

27) Liu S, et al : Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease : results from a cross-sectional study in China. Thorax 72 : 788-795, 2017.

28) Gauderman WJ, et al : The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 351 : 1057-1067, 2004.

29) Gauderman WJ, et al : Association of improved air quality with lung development in children. N Engl J Med 372 : 905-913, 2015.

30) Craig TJ, et al : Advances in managing COPD related to α1-antitrypsin deficiency : an under-recognized genetic disorder. Allergy 2018 [Epub ahead of print].

31) 日本呼吸器学会 : α1-アンチトリプシン欠乏症診療の手引き 2016. 日本呼吸器学会, 東京, 2016.

32) Yuan C, et al : Genetic polymorphism and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 12 : 1385-1393, 2017.

33) Bui DS, et al : Childhood predictors of lung function trajectories and future COPD risk : a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med 6 : 535-544, 2018.

34) de Marco R, et al : Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 183 : 891-897, 2011.

35) Bigna JJ, et al : Prevalence of chronic obstructive pulmonary disease in the global population with HIV : a systematic review and meta-analysis. Lancet Glob Health 6 : e193-e202, 2018.

36) Byrne AL : Tuberculosis and chronic respiratory disease : a systematic review. Int J Infect Dis 32 : 138-146, 2015.

37) Sze MA, et al : Host response to the lung microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 : 438-445, 2015.

38) Silva GE, et al : Asthma as a risk factor for COPD in a longitudinal study. Chest 126 : 59-65, 2004.

39) Serheim IC, et al : Gender differences in COPD : are women more susceptible to smoking effects than men? Thorax 65 : 480-485, 2010.

40) Hardin M, et al : Sex-specific features of emphysema among current and former smokers with COPD. Eur Respir J 47 : 104-112, 2016.

P.57 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会編 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. メディカルレビュー社, 東京, 2018.

2) 日本呼吸器学会喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018作成委員会編 : 喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018. メディカルレビュー社, 東京, 2017.

3) Diaz-Guzman E, et al : Asthma, chronic obstructive pulmonary disease, and mortality in the U. S. population. COPD 8 : 400-407, 2011.

4) Matsumoto K, et al : Prevalence of asthma with airflow limitation, COPD, and COPD with variable airflow limitation in older subjects in a general Japanese population : the Hisayama Study. Respir Investig 53 : 22-29, 2015.

5) Fu JJ, et al : Longitudinal changes in clinical outcomes in older patients with asthma, COPD and asthma-COPD overlap syndrome. Respiration 87 (1) : 63-74, 2014.

6) van Boven JF, et al : Comorbidome, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life. Chest 149 (4) : 1011-1020, 2016.

7) Soriano JB, et al : The proportional Venn diagram of obstructive lung disease : two approximations from the United States and the United Kingdom. Chest 124 (2) : 474-481, 2003.

8) Kurashima K, et al : COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 11 : 479-487, 2016.

9) Kitaguchi Y, et al : Comparison of pulmonary function in patients with COPD, asthma COPD overlap syndrome, and asthma with airflow limitation. Int J Chron Obstruct Pulmon Dis 11 : 991-997, 2016.

10) Yamauchi Y, et al : Comparison of in-hospital mortality in patients with COPD, asthma and asthma-COPD overlap exacerbations. Respirology 20 (6) : 940-946, 2015.

11) Kornum JB, et al : Chronic obstructive pulmonary disease and cancer risk : a Danish nationwide cohort study. Respir Med 106 : 845-852, 2012.

12) Nakayama M, et al : Risk of cancers in COPD patients. Chest 123 : 1775-1776, 2003.

13) Global Initiative for Chronic Obstructive Lung Disease : Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018 Report. <https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf>

14) Mannino DM, et al : Low lung function and incident lung cancer in the United States : data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 163 : 1475-1480, 2003.

15) Young RP, et al : COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 34 : 380-386, 2009.

16) Abal Arca J, et al : Lung cancer and COPD : a common combination. Arch Bronconeumol 45 : 502-507, 2009.

17) Loganathan RS, et al : Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 129 : 1305-1312, 2006.

18) de Torres JP, et al : Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 132 : 1932-1938, 2007.

19) Wilson DO, et al : Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 178 : 738-744, 2008.

20) de-Torres JP, et al : Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med 191 : 285-291, 2015.

21) Papi A, et al : COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 59 : 679-681, 2004.

22) Hashimoto N, et al : Clinical impact of prevalence and severity of COPD on the decision-making process for therapeutic management of lung cancer patients. BMC Pulm Med 14 : 14, 2014.

23) de Torres JP, et al : Lung cancer in patients with chronic obstructive pulmonary disease Incidence and predicting factors. Am J Respir Crit Care Med 184 : 913-919, 2011.

24) Timmerman R, et al : Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA 303 : 1070-1076, 2010.

25) Nagata Y, et al : Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer : Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 93 : 989-996, 2015.

26) Shirvani SM, et al : Lobectomy, sublobar resection, and stereotactic abiative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 149 : 1244-1253, 2014.

27) Takeda A, et al : Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest 141 : 858-866, 2012.

28) Hara Y, et al : Stereotactic body radiotherapy for chronic obstructive pulmonary disease patients undergoing or eligible for long-term domiciliary oxygen therapy. J Radiat Res 57 : 62-67, 2016.

29) Auerbach O, et al : Relation of smoking and age to findings in lung parenchyma : a microscopic study. Chest 65 : 29-35, 1974.

30) Cottin V, et al : Combined pulmonary fibrosis and emphysema : a distinct underrecognised entity. Eur Respir J 26 : 586-593, 2005.

31) Washko GR, et al : Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 364 : 897-906, 2011.

32) Mejia M, et al : Idiopathic pulmonary fibrosis and emphysema : decreased survival associated with severe pulmonary arterial hypertension. Chest 136 : 10-15, 2009.

33) Papaioannou AI, et al : Combined pulmonary fibrosis and emphysema : The many aspects of a cohabitation contract Respir Med 117 : 14-26, 2016.

34) Koo HJ, et al : Lung Cancer in Combined Pulmonary Fibrosis and Emphysema : A Systematic Review and Meta-Analysis. PLoS One 11 : e0161437, 2016.

P.66 掲載の参考文献

1) 日本呼吸器学会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. メディカルレビュー社, 東京, 2018.

2) Barnes P J, et al : Systemic manifestations and comorbidities of COPD. Eur Respir J 33 : 1165-1185, 2009.

3) Handschin C, et al : The role of exercise and PGC1alpha in inflammation and chronic disease. Nature 454 (7203) : 463-469, 2008.

4) Takahashi S, et al : The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir Investig 53 (6) : 259-270, 2015.

5) Smith MC, et al : Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis 9 : 871-888, 2014.

6) Divo M, et al : Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186 (2) : 155-161, 2012.

7) Gan WQ, et al : Association between chronic obstructive pulmonary disease and systemic inflammation : a systematic review and a meta-analysis. Thorax 59 : 574-580, 2004.

8) Moy ML, et al : Daily step count is associated with plasma C-reactive protein and IL-6 in a US cohort with COPD. Chest 145 : 542-550, 2014.

9) Chen W, et al : Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease : a systematic review and meta-analysis. Lancet Respir Med 3 (8) : 631-639, 2015.

10) Ohara T, et al : Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 134 : 1244-1249, 2008.

11) Hersh CP, et al : Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med 14 : 164, 2014.

12) Martineau AR, et al : Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO) : a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 3 (2) : 120-130, 2015.

13) Yoshikawa M, et al : Distribution of muscle mass and maximal exercise performance in patients with COPD. Chest 119 : 93-98, 2001.

14) Jones SE, et al : Sarcopenia in COPD : prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 70 : 213-218, 2015.

15) Miyamoto K, et al : Gender effect on prognosis of patients receiving long-term home oxygen therapy. The Respiratory Failure Research Group in Japan. Am J Respir Crit Care Med 152 : 972-976, 1995.

16) Shibata Y, et al : A lower level of forced expiratory volume in 1 second is a risk factor for all-cause and cardiovascular mortality in a Japanese population : the Takahata study. PLoS One 8 (12) : e83725, 2013.

17) Bhatt SP, et al : β-Blockers are associated with a reduction in COPD exacerbations, Thorax 71 (1) : 8-14, 2016.

18) Terada K, et al : Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 63 : 951-955, 2008.

19) 川山智隆, 他 : COPDの併存症とその治療. うつ, 睡眠障害. 呼吸器内科 6 (6) : 577-584, 2013.

20) Shawon MS, et al : Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease : A systematic review. Sleep Med Rev 32 : 58-68, 2017.

21) Marin JM, et al : Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea : the overlap syndrome. Am J Respir Crit Care Med 182 : 325-331, 2010.

22) Azuma M, et al : Associations among chronic obstructive pulmonary disease and sleep-disordered breathing in an urban male working population in Japan. Respiration 88 (3) : 234-243, 2014.

P.68 掲載の参考文献

1) Copley SJ, et al : Radiology 251 : 566, 2009.

2) Winter DH, et al : Lung 193 : 283, 2015.

3) Araki T, et al : Thorax 70 : 1156, 2015.

第3章診断

P.76 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD診断と治療のためのガイドライン 2018. メディカルビュー社, 東京, 2018.

2) Woodruff PG, et al : Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med 374 : 1811-1821, 2016.

3) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease : Global Initiative for Chronic Obstructive Lung Disease ; 2011. <http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html> (accessed July 20, 2018).

4) Bestall JC, et al : Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54 : 581-586, 1999.

5) Nishimura K, et al : Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121 : 1434-1440, 2002.

6) Waschki B, et al : Physical activity is the strongest predictor of all-cause mortality in patients with COPD : a prospective cohort study. Chest 140 (2) : 331-342, 2011.

7) Agusti A, et al : Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11 : 122, 2010.

8) Divo M, et al : Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186 : 155-161, 2012.

9) GlaxoSmithKline group of companies : COPD Assessment test. <http://www.catestonline.org>

10) van der Molen T, et al : Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 1 : 13, 2003.

11) International Primary Care Airways Group (IPAG) <http://www.ipag.org>

12) Martinez FJ, et al : COPD-PS Clinician Working Group : Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD 5 : 85-95, 2008.

13) Samukawa T, et al : Development of a self-scored persistent airflow obstruction screening questionnaire in a general Japanese population : the Hisayama study. Int J Chron Obstruct Pulmon Dis 12 : 1469-1481, 2017.

14) 横山彰仁 : COPD診断 : 身体所見. Mebio 30 : 29-33, 2013.

15) Johnston CR 3rd, et al : The Hoover's Sign of Pulmonary Disease : Molecular Basis and Clinical Relevance. Clin Mol Allergy 6 : 8, 2008.

16) Kilburn KH, et al : Anteroposterior chest diameter in emphysema. From maxim to measurement. Arch Intern Med 123 : 379-382, 1969.

17) Baughman RP, et al : Prevalence of digital clubbing in bronchogenic carcinoma by a new digital index. Clin Exp Rheumatol 16 : 21-26, 1998.

P.83 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会編集 : COPD慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. 株式会社メディカルレビュー社, 東京, 2018.

2) 橋本修, 他 : 慢性閉塞性肺疾患 (COPD) 患者および喘息合併患者における治療の現状-インターネット調査より. Prog Med 33 : 355-362, 2013.

3) 一般社団法人日本呼吸器学会喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き2018作成委員会編集 : 喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018. 株式会社メディカルレビュー社, 東京, 2017.

4) Kitaguchi Y, et al : Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. COPD 7 : 1-7, 2012.

5) O'Donnell DE, et al : Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 : 770-777, 2001.

6) 一般社団法人日本呼吸器学会「肺の健康」啓発推進委員会編 : 肺年齢ハンドブック-肺年齢測定と肺機能検査の実際-. 株式会社メディカルレビュー社, 東京, 2009.

7) 一般社団法人日本呼吸器学会肺生理専門委員会編集 : 臨床呼吸機能講習会テキスト第8版. 株式会社メディカルレビュー社, 東京, 2016.

8) Kitaguchi Y, et al : Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 100 : 1742-1752, 2006.

9) West J : Respiratory Physiology-the essentials. The Willams 8. Wilkins Company. Baltimore, 1974.

10) Mori K, et al : Colored 3-Dimensional analysis of respiratory resistance and reactance in COPD and asthma. COPD 8 : 456-463, 2011.

11) Wada Y, et al : Diversity of respiratory impedance based on quantitative computed tomography in patients with COPD. Int J Chron Obstruct Pulmon Dis 13 : 1841-1849, 2018.

12) Kanda S, et al : Evaluation of respiratory impedance in asthma and COPD by an impulse oscillation system. Intern Med 49 : 23-30, 2010.

13) Nishimura M, et al : Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. AJRCCM 185 : 44-52, 2012.

14) Hurst JR, et al : Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 : 1128-1138, 2010.

P.91 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会編 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. 2018.

2) Bergin C, et al : The diagnosis of emphysema : A computed tomographic-pathologic correlation. Am Rev Respir Dis 133 : 541-546, 1986.

3) Goddard PR, et al : Computed tomography in pulmonary emphysema. Clin Radiol 33 : 379-387, 1982.

4) Muller NL, et al : "Density Mask" : An objective method to quantitate emphysema using computed tomography. Chest 94 : 782-787, 1988.

5) Gevenois PA, et al : Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 152 : 653-657, 1995.

6) Sakai, N, et al : An automated method to assess the distribution of low attenuation areas on chest CT scans in chronic pulmonary emphysema patients. Chest 106 : 1319-1325, 1994.

7) Mishima M, et al : Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 96 : 8829-8834, 1999.

8) Coxson HO, et al : New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180 : 588-597, 2009.

9) Greene R, et al : 'Saber-Sheath' trachea : A clinical and functional study of marked coronal narrowing of the intrathoracic trachea. Radiology 115 : 258-265, 1975.

10) Nakano Y, et al : Quantitative assessment of airway remodeling using high-resolution CT. Chest 122 (6 Suppl) : 271S-275S, 2002.

11) Hasegawa M, et al : Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 : 1309-1315, 2006.

12) Oguma T, et al : Longitudinal shape irregularity of airway lumen assessed by CT in patients with bronchial asthma and COPD. Thorax 70 (8) : 719-724, 2015.

13) Oguma T, et al : Limitations of airway dimension measurement on images obtained using multidetector row computed tomography. PLoS One 8 (10) : e76381, 2013.

14) Matsuoka S, et al : Quantitative CT measurement of cross-sectional area of small pulmonary vessel in COPD : correlations with emphysema and airflow limitation. Acad Radiol 17 (1) : 93-99, 2010.

15) Ohara T, et al : Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 134 (6) : 1244-1249, 2008.

16) Tanimura K, et al : Quantitative Assessment of Erector Spinae Muscles in Patients with Chronic Obstructive Pulmonary Disease. Novel Chest Computed Tomography-derived Index for Prognosis. Ann Am Thorac Soc 13 (3) : 334-341, 2016.

17) Ohno Y, et al : Oxygen-enhanced magnetic resonance imaging versus computed tomography. Multicenter study for clinical stage classification of smoking-related chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177 : 1095-1102, 2008.

P.99 掲載の参考文献

1) Agusti A : The path to personalised medicine in COPD. Thorax 69 (9) : 857-864, 2014.

2) McDonough JE, et al : Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365 (17) : 1567-1575, 2011.

P.104 掲載の参考文献

1) Oga T, et al : Am J Respir Crit Care Med 167 : 544, 2003.

2) Watz H, et al : Eur Respir J 44 : 1521, 2014.

3) Puente-Maestu L, et al : Eur Respir J 47 : 429, 2016.

4) Maekura R, et al : Respir Care 59 : 252, 2014.

5) 日本呼吸器学会COPDガイドライン第5版作成委員会編 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン. 2018.

6) Kagawa H, et al : Front Physiol (in press).

7) Johnston AK, et al : Thorax 63 : 599, 2008.

8) Rutten FH, et al : Eur Heart J 26 : 1887, 2005.

9) Onishi K, et al : Int J Chron Obstruct Pulmon Dis 9 : 563, 2014.

10) Vaes AW, et al : Eur Respir J 44 : 1199, 2014.

11) Edahiro R, et al : ATS 2018 International Conference 2018.

12) Miki K, et al : J Breath Res 12 : 036008, 2018.

13) O'Donnell DE, et al : Eur Respir Rev 25 : 333, 2016.

14) Miki K, et al : Respirology 14 : 1020, 2009.

15) Miki K, et al : Respiroiogy 17 : 149, 2012.

16) Miki K, et al : Respir Physiol Neurobiol 185 : 653, 2013.

17) 三木啓資, 他 : 第58回日本呼吸器学会学術講演会 2018.

第4章管理・治療

P.110 掲載の参考文献

1) Fukuchi Y, et al : COPD in Japan : the Nippon COPD Epidemiology study. Respirology 9 : 458-465, 2004.

2) 日本呼吸器学会COPDガイドライン第5版作成委員会編 : COPD慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版 2018. メディカルレビュー社, 東京, 2018.

3) Donaldson GC, et al : Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 : 847-852, 2002.

4) Soler-Cataluna JJ, et al : Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 : 925-931, 2005.

5) Woodruff PG, et al : Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med 374 : 1811-1821, 2016.

6) Lindberg A, et al : Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 129 : 879-885, 2006.

7) Regan EA, et al : Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med 175 : 1539-1549, 2015.

8) Vogelmeier C, et al : Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364 : 1093-1103, 2011.

9) Decramer ML, et al : Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE) : a randomised, blinded, parallel-group study. Lancet Respir Med 1 : 524-533, 2013.

10) 日本呼吸器学会喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き2018作成委員会編 : 喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018. メディカルレビュー社, 東京, 2017.

P.117 掲載の参考文献

1) Doll R, et al : Mortality in relation to smoking : 50 years' observations on male British doctors. BMJ 328 : 1519, 2004.

2) Sakata R, et al : Impact of smoking on mortality and lie expectancy in Japanese smokers : a prospective cohort study. BMJ 345 : e7093, 2012.

3) U. S. Department of Health and Human Services : The Health Consequences of Involuntary Exposure to Tabacco Smoke : A Report of the Surgeon GeneraL Atlamta, GA : U. S. Department of Health and Human Services, Centers for Disease Condtrol and Prevention, Coordinating Center for Health Promotion, National Center for Chornic Disease Prevention and Health Promotion, Office on Smoking nad Health, 2006.

4) WHO FCTC overview. WHO Framework Convention on Tabacco Control. <http://www.who.int/fctc/about/WHO_FCTC_summary_January2015.pdf?ua=1>

5) 日本禁煙学会 : FCTC (タバコ規制枠組条約) ポケットブック. <www.nosmoke55.jp/action/fctcpocketbook.doc>

6) Media Center, WHO statement WHO to establish high-level commission on noncommunicable diseases. 2017. <http://www.who.int/mediacentre/news/statements/2017/ncd-commission/en/>

P.123 掲載の参考文献

1) Stehi S : Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117 : 380S-385S, 2000.

2) Poole PJ, et al : Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1 : CD002733, 2006.

3) Nicol KL, et al : Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357 : 1373-1381, 2007.

4) Kiyohara K, et al : Changes in COPD mortality rate after amendments to the Preventive Vaccination Law in Japan. Eur J Public Health 23 : 133-139, 2013.

5) Pollard AJ, et al : maintaining protection against invasive bacteria with protein-polysaccharide conj ugate vaccines. Nat Rev Immunol 9 : 213-220, 2009.

6) Maruyama T, et al : Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents : double blind, randomised and placebo controlled trial. BMJ 340 : c1004, 2010.

7) Bonten MJ, et al : Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372 : 1114-1125, 2015.

8) Alfageme I, et al : Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61 : 189-195, 2006.

9) Walters JA, et al : Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1 : CD001390, 2017.

10) Tomczyk S, et al : Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≧ 65 years : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 63 (37) : 822-825, 2014.

11) Greenberg RN, et al : Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 32 : 2364-2374, 2014.

12) Christenson B, et al : Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J 5 : 52, 2008.

13) Kawakami K, et al : Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28 (43) : 7063-7069, 2010.

14) Furumoto A, et al : Additive effect of pneumococcal vaccine and infiuenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 26 : 4284-4289, 2008.

15) McLaughlin JM, et al : Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults : A Test-Negative Design. Clin Infect Dis 2018 [Epub ahead of print].

P.132 掲載の参考文献

1) Donald P, et al : A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 359 : 1543-1554, 2008.

2) Vogelmeier C, et al : Tiotropium versus Salmeterol for the Preventionof Exacerbations of COPD. N Engl J Med 364 (12) : 1093-1103, 2011.

3) Decramer ML, et al : Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE) : a randomised, blinded, parallel-group study. Lancet Respir Med 1 (7) : 524-533, 2013.

4) Bateman ED, et al : Dual bronchodilation with QVA149 versus single bronchodilator therapy : the SHINE study. Eur Respir J 42 (6) : 1484-1494, 2013.

5) Asai K, et al : Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD : Pooled analysis of SHINE and ARISE. Respir Investig 54 (6) : 428-435, 2016.

6) Wedzicha JA, et al : Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK) : a randomised, double-blind, parallel-group study. Lancet Respir Med 1 : 199-209, 2013.

7) Calverley PMA, et al : Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO) : a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med 6 (5) : 337-344, 2018.

8) Ichinose M, et al : Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD : results from the DYNAGITO study. Int J Chron Obstruct Pulmon Dis 31 : 2147-2156, 2018.

9) Zheng JP, et al : Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study) : a randomized placebo controlled study. Lancet 371 : 2013-2018, 2008.

10) Zheng JP, et al : Twice daily N-acetylcysteine 600mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON) : a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2 (3) : 187-194, 2014.

11) Crim C, et al : Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation : The SUMMIT trial. Respir Med 131 : 27-34, 2017,

12) Jorgen V, et al : Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY) : a double-blind, parallel group, randomised controlled trial. Lancet 389 : 1919-1929, 2017.

13) Papi A, et al : Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE) : a double-blind, parallel group, randomised controlled trial. Lancet 391 : 1076-1084, 2018.

14) Lipson DA, et al : Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 378 (18) : 1671-1680, 2018.

P.139 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD診断と治療のためのガイドライン 2018. p91-94. メディカルレビュー社, 東京, 2018.

2) Makita H, et al : Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 62 (11) : 932-937, 2007.

3) Konno S, et al : Acute bronchodilator responses to β2-agonist and anticholinergic agent in COPD : Their different associations with exacerbation. Respir Med 127 : 14-20, 2017.

4) Hasegawa M, et al : Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax 64 (4) : 332-338, 2009.

5) Shimizu K, et al : Regional bronchodilator response assessed by computed tomography in chronic obstructive pulmonary disease. Eur J Radiol 84 (6) : 1196-1201, 2015.

6) Suzuki M, et al : Asthma-like features and clinical course of obstructive pulmonary disease. an analysis from the Hokkaido COPD cohort study. Am J Respir Crit Care Med 194 (11) : 1358-1365, 2016.

7) Nishimura M, et al : Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 185 : 44-52, 2012.

P.146 掲載の参考文献

1) Calverley PM, et al : Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 : 775-789, 2007.

2) Szafranski W, et al : Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 : 74-81, 2003.

3) Crim C, et al : Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination : TORCH study results. Eur Respir J 34 : 641-647, 2009.

4) Hubbard R, et al : Use of inhaled corticosteroids and the risk of fracture. Chest 130 : 1082-1088, 2006.

5) Wedzicha JA, et al : Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 374 : 2222-2234, 2016.

6) Magnussen H, et al : Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371 : 1285-1294, 2014.

7) 日本呼吸器学会 : COPDガイドライン第5版作成委員会 : COPD診断と治療のためのガイドライン [第5版]. 2018.

8) McDonald VM, et al : Multidimensional assessment and tailored intervelltions for COPD : respiratory utopia or common sense? Thorax 68 (7) : 691-694, 2013.

9) Leigh R, et al : Stable COPD : predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 27 : 964-971, 2006.

10) Pascoe S, et al : Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease : a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 : 435-442, 2015.

11) Akamatsu K, et al : Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease : What is the Specific Marker? Front Pharmacol 2 : 36, 2011.

12) Yoshikazu Yamaji, et al : Detection of Biomarkers of Steroid Response in COPD (De-Stress Study). Am J Respir Crit Care Med 197 : A1010, 2018.

13) 一般社団法人日本呼吸器学会 : 喘息とCOPDオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き2018作成委員会 : 喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018. 2018.

P.152 掲載の参考文献

1) Waschki B, et al : Physical activity is the strongest predictor of all-cause mortality in patients with COPD : a prospective cohort study. Chest 140 (2) : 331-342, 2011.

2) Cavalheri V, et al : Changing physical activity and sedentary behaviour in people with COPD. Respirology 21 (3) : 419-426, 2016.

3) Eliason G, et al : Physical activity patterns in patients in different stages of chronic obstructive pulmonary disease. COPD 8 (5) : 369-374, 2011.

4) Ichinose M, et al : Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity. Int J Chron Obstruct Pulmon Dis 13 : 1407-1419, 2018.

5) Sugino A, et al : Validation of a compact motion sensor for the measurement of physical activity in patients with chronic obstructive pulmonary disease. Respiration 83 (4) : 300-307, 2012.

6) Miyamoto S, et al : Verification of a Motion Sensor for Evaluating Physical Activity in COPD Patients. Carl Respir J 8343705 : 1-8, 2018.

7) Byrom B, et al : Measuring free-living physical activity in COPD patients : Deriving methodology standards for clinical trials through a review of research studies. Contemp Clin Trials 47 : 172-184, 2016.

8) Pitta F, et al : Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 (9) : 972-977, 2005.

9) Sakamoto Y, et al : Walking Pattern in COPD Patients. Rehabil Nurs 41 : 211-217, 2016.

10) Minakata Y, et al : Reduced level of physical activity in Japanese patients with chronic obstructive pulmonary disease. Respir Investig 52 (1) : 41-48, 2014.

11) Hayata A, et al : Differences in physical activity according to mMRC grade in patients with COPD. Int J Chron Obstruct Pulmon Dis 11 : 2203-2208, 2016.

12) Tanimura K, et al : Quantitative Assessment of Erector Spinae Muscles in Patients with Chronic Obstructive Pulmonary Disease. Novel Chest Computed Tomography-derived Index for Prognosis. Ann Am Thorac Soc 13 (3) : 334-341, 2016.

13) Minakata Y, et al : Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 10 : 1275-1282, 2015.

14) Kesten S, et al : Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 3 (1) : 127-136, 2008.

15) Mendoza L, et al : Pedometers to enhance physical activity in COPD : arandomised controlled trial. Eur Respir J 45 (2) : 347-354, 2015.

16) Pleguezuelos E, et al : Improving physical activity in patients with COPD with urban walking circuits. Respir Med 107 (12) : 1948-1956, 2013.

P.160 掲載の参考文献

1) 日本呼吸ケア・リハビリテーション学会 (旧日本呼吸管理学会) 呼吸リハビリテーションガイドライン作成委員会, 他 : 日本呼吸ケア・リハビリテーション学会 (旧日本呼吸管理学会), 日本呼吸器学会 : 呼吸リハビリテーションに関するステートメント. 日呼管誌 11 : 321-330, 2001.

2) 日本呼吸ケア・リハビリテーション学会 (旧日本呼吸管理学会) 呼吸リハビリテーションガイドライン作成委員会, 他 : 日本呼吸ケア・リハビリテーション学会 (旧日本呼吸管理学会), 日本呼吸器学会 : 呼吸リハビリテーションに関するステートメント. 日呼吸会誌 40 : 536-544, 2002,

3) 日本呼吸ケア・リハビリテーション学会 (旧日本呼吸管理学会) 呼吸リハビリテーションガイドライン作成委員会, 他 : 呼吸リハビリテーションマニュアル-運動療法-. 照林社, 東京, 2003.

4) 日本呼吸ケア・リハビリテーション学会呼吸リハビリテーション委員会, 他 : 呼吸リハビリテーションマニュアル-患者教育の考え方と実践-. 照林社, 東京, 2007.

5) 日本呼吸ケア・リハビリテーション学会呼吸リハビリテーション委員会ワーキンググループ, 他 : 呼吸リハビリテーションマニュアル-運動療法- 第2版. 照林社, 東京, 2012.

6) 3学会合同呼吸リハビリテーションに関するステートメントワーキンググループ, 他 : 日本呼吸ケア・リハビリテーション学会, 日本呼吸理学療法学会, 日本呼吸器学会. 呼吸リハビリテーションに関するステートメント. 日呼ケアリハ学誌 27 (2) : 95-114, 2018.

7) Spruit MA, et al : An official American Thoracic Society/European Respiratory Society statement : key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188 : e13-e64, 2013.

8) Ueki J, et al : Evaluation of the differences in elements of physiotherapy techniques for patients with chronic pulmonary diseases between Japan and UK. Respirology 14 (Suppl 3) : A191, 2009.

9) Osadnik CR, et al : Principles of rehabilitation and reactivation. Respiration 89 (1) : 2-11, 2015.

10) Watz H, et al : An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 44 : 1521-1537, 2014.

11) 植木純 : 運動療法とセルフマネジメント教育. 日呼ケアリハ学誌 22 : 335-338, 2012.

12) 植木純 : セルフマネジメント教育を支援する日本初の新世代モバイルアプリケーション. 順天堂だより 299 : 3-4, 2018.

13) McCabe C, et al : Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease. Cochrane Database Syst Rev 5 : CD011425, 2017.

14) Chatwin M, et al : Randomised crossover trial of telemonitoring in chronic respiratory patients (TeleCRAFT trial). Thorax 71 (4) : 305-311, 2016.

15) Sano E, et al : Self-management education using interactive application software for tablet computer to improve health status in patients with COPD : a randomized controlled trial. Eur Respir J 48 : (Suppl 60) : PA3736, 2016.

16) Rochester CL, et al : An Official American Thoracic Society/European Respiratory Society Policy Statement : Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med 192 : 1373-1386, 2015.

P.168 掲載の参考文献

1) King DA, et al : Nutritional aspects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 (4) : 519-523, 2008.

2) 吉川雅則, 他 : 栄養障害. 日内会誌 101 : 1562-1570, 2012.

3) Varraso R, et al : Alternative healthy eating index 2010 and risk of chronic obstructive pulmonary disease among US women and men : prospective study. BMJ 350 : h286, 2015.

4) Salari-Moghaddam A, et al : Processed red meat intake and risk of COPD : A systematic review and dose-response meta-analysis of prospective cohort studies. Clin Nutr 2018 [Epub ahead of print].

5) Kaluza J, et al : Fruit and vegetable consumption and risk of COPD : a prospective cohort study of men. Thorax 72 : 500-509, 2017.

6) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. メディカルレビュー社, 東京, 2018.

7) Cao C, et al : Body mass index and mortality in chronic obstructive pulmonary disease : a meta-analysis. PLoS one 7 (8) : e43892, 2012.

8) Vestbo J, et al : Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample : findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173 (1) : 79-83, 2006.

9) Yoshikawa M, et al : Mini Nutritional Assessment Short-Form predicts exacerbation frequency in patients with chronic obstructive pulmonary disease. Respirology 19 : 1198-1203, 2014.

10) Zhu M, et al : The association between vitamin D and COPD risk, severity, and exacerbation : an updated systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 11 : 2597-2607, 2016.

11) Maltais F, et al : An official American Thoracic Society/European Respiratory Society statement : update on limb muscle dysfunction in chronic obstructive pulmonary disease. AJRCCM 189 : e15-e62, 2014.

12) Tanimura K, et al : Quantitative Assessment of Erector Spinae Muscles in Patients with Chronic Obstructive Pulmonary Disease. Novel Chest Computed Tomography-derived Index for Prognosis. Ann Am Thorac Soc 13, (3) : 334-341, 2016.

13) de Blasioa F, et al : Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables. Respir Med 134 : 1-5, 2018.

14) Limpawattana P, et al : Sarcopenia in chronic obstructive pulmonary disease : A study of prevalence and associated factors in the Southeast Asian population. Chron Respir Dis 2017 [Epub ahead of print].

15) Byun MK, et al : Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis 12 : 669-675, 2017.

16) Hwang JA, et al : Clinical Implications of Sarcopenia on Decreased Bone Density in Men With COPD. Chest 151 (5) : 1018-1027, 2017.

17) Schols AM, et al : Nutritional assessment and therapy in COPD : a European Respiratory Society statement. Eur Respir J 44 (6) : 1504-1520, 2014.

18) ASPEN Board of Directors and the Clinical Guidelines Task Force : Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 26 (1 Suppl) : 1SA-138SA, 2002.

19) Dal Negro RW, et al : Essential amino acid supplementation in patients with severe COPD : a step towards home rehabilitation. Monaldi Arch Chest Dis 77 (2) : 67-75, 2012.

20) Deutz NE, et al : Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement : A randornized clinical trial. Clin Nutr 35 : 18-26, 2016.

21) Fulton AS, et al : Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease : a systematic review. Nutr Rev 73 (9) : 612-623, 2015.

22) Mathyssen C, et al : Vitamin D supplementation in respiratory diseases : evidence from randomized controlled trials. Pol Arch Intern Med 127 (11) : 775-784, 2017.

23) van de Bool C, et al : A randomized clinical trial investigating the efflcacy of targeted nutrition as adlunct to exercise training in COPD. J Cachexia Sarcopenia Muscle 8 : 748-758, 2017.

24) Ashitani J, et al : Effect of octanoic acid-rich formula on plasma ghrelin levels in cachectic patients with chronic respiratory disease. Nut J 8 : 25, 2009.

25) Ferreira IM, et al : Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12 : CD000998, 2012.

26) Collins PF, et al : Nutritional support in chronic obstructive pulmonary disease : a systematic review and meta-analysis. Am J Clin Nutr 95 (6) : 1385-1395, 2012.

P.177 掲載の参考文献

1) 在宅呼吸ケア白書ワーキンググループ編 : 在宅呼吸ケア白書 2010. メディカルレビュー社, 大阪, 2010.

2) Nocturnal oxygen therapy trial group : Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease : a clinical trial. Ann Intern Med 93 : 391-398, 1980.

3) Report of the Medical Research Council Working Party : Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1 : 681-686, 1981.

4) Calverley PM, et al : The effect of oxygenation on sleep quality in chronic bronchitis and emphysema. Am Rev Respir Dis 126 : 206-210, 1982.

5) Gorecka D, et al : Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 52 : 674-679, 1997.

6) Chaouat A, et al : A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J 14 : 1002-1008, 1999.

7) Ekstrom MP, et al : The management of chronic breathlessness in patients with advanced and terminal illness. BMJ 349 : g7617, 2015.

8) Petty TL, et al : Ambulatory oxygen therapy, exercise, and survival with advanced chronic obstructive pulmonary disease (the Nocturnal Oxygen Therapy Trial revisited). Respir Care 45 : 204-211, 2000.

9) Hardinge M, et al : British Thoracic Society guidelines for home oxygen use in adults. British Thoracic Society Standards of Care Committee. Thorax 70 : i1-i43, 2015.

10) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン. 2018.

11) Casanova C, et al : Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest 134 : 746-752, 2008.

12) 日本呼吸ケア・リハビリテーション学会酸素療法マニュアル作成委員会 : 日本呼吸器学会肺生理専門委員会編 : 酸素療法マニュアル. メディカルレビュー社, 大阪, 2018.

13) Austin MA, et al : Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting : randomised controlled trial. BMJ 341 : c5462, 2010.

14) 日本呼吸器学会NPPVガイドライン作成委員会編 : NPPV (非侵襲的陽圧換気療法) ガイドライン改訂第2版. 南江堂, 東京, 2015.

15) Lightowler JV, et al : Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease : Cochrane systematic review and meta-analysis. BMJ 326 : 185, 2003.

16) Kohnlein T, et al : Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease : a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2 : 698-705, 2014.

P.191 掲載の参考文献

1) Global Initiative for Chronic Obstructive Lung Disease : Lung Disease POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION A Guide for Health Care Professionals. 2017.

2) Cooper JD, et al : Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 116 : 109-193, 1995.

3) McKenna RJ Jr, et al : Should lungvolume reduction surgery be unilateral or bilateral. J Thorac Cardiovascular Surg 112 : 1331-1339, 1996.

4) American Thoracic Society Medical Section of the American Lung Association : Lung volume reduction surgery. Am J Respir Crit Care Med 154 : 1151-1152, 1996.

5) NHLBI Workshop Summary : Evaluation and research in lung volume reduction surgery. Am J Respir Crit Care Med 154 : 1913-1918, 1996.

6) Cooper JD, et al : Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 112 : 1319-1329 ; discussion 1329-1330, 1996.

7) Young J, et al : Lung volume reduction surgery (LVRS) for chronic obstructive pulmonary disease (COPD) with underlying severe emphysema. Thorax 54 : 779-789, 1999.

8) Stirling GR, et al : Lung volume reduction surgery in emphysema : a systematic review. Ann Thorac Surg 72 : 330-333, 2001.

9) O'Donnell DE, et al : Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest 110 : 18-27, 1996.

10) Takayama T, et al : Effects of lung volume reduction surgery for emphysema on oxygen cost of breathing. Chest 123 : 1847-1852, 2003.

11) Ferguson GT, et al : Improved exercise performance following lung volume reduction surgery for emphysema. Am J Respir Crit Care Med 157 : 1195-1203, 1998.

12) Benditt JO, et al : Lung volume reduction surgery improves maximal O2 consumption, maximal minute ventilation, O2 pulse, and dead space-to-tidal volume ratio during leg cycle ergometry. Am J respire Crit Care Med 156 : 561-566, 1997.

13) Martinez FJ, et al : Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 155 : 1984-1990, 1997.

14) Block KE, et al : Effect of surgical lung volume reduction on breathing patterns in severe pulmonary emphysema. Am J Respir Crit Care Med 156 : 553-560, 1997.

15) Gelb AF, et al : Mechanism of short term improvement in lung function after emphysema resection. Am J Respir Crit Care Med 154 : 945-951, 1996.

16) Ingenito EP, et al : Improvement in pulmonary function and elastic recoil after lung reduction surgery for diffuse emphysema. N Engl J Med 334 : 1095-1099, 1996.

17) Fessler HE, et al : Improvement in spirometry following lung volume reduction surgery : application of a physiologic model. Am J Respir Crit Care Med 165 : 34-40, 2002.

18) McKenna RJ Jr, et al : Should lung volume reduction for emphysema be unilateral or bilateral? J Thorac Cardiovasc Surg 112 (5) : 1331-1339, 1996.

19) GELB AF, et al : Lung Function 5 yr after Lung Volume Reduction Surgery for Ernphysema. Am J Respir Crit Care Med 163 (7) : 1562-1566, 2001.

20) McKenna RJ Jr, et al : Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery. J Thorac Cardiovasc Surg 127 : 1350-1360, 2004.

21) National Emphysema Treatment Trial Research Group : Patients at high risk of death after LVRS. N Engl J Med 345 : 1075-1083, 2001.

22) National Emphysema Treatment Trial Research Group : A randomized trial comparing lung volume reduction surgery with medical therapy for severe emphysema. N Engl J Med 348 : 2059-2073, 2003.

23) Ciccone AM, et al : Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thorac Cardiovasc Surg 125 : 513-525, 2003.

24) Sanchez PG, et al : National Emphysema Treatment Trial redux : accentuating the positive. J Thorac Cardiovasc Surg 140 (3) : 564-572, 2010.

25) Naunheim KS, et al : Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 82 : 431-443, 2006.

26) Patel N, et al : Lung Transplantation and Lung Volume Reduction Surgery versus Transplantation in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 5 : 447-453, 2008.

27) Rogers RM, et al : Preoperative severity of emphysema predictive of improvement after lung volume reduction surgery. Use of CT morphometry. Chest 118 : 1240-1247, 2000.

28) Imfeld S, et al : The BODE index after lung volume reduction surgery correlates with survival. CHEST 129 : 873-878, 1996.

29) Chihara K : Lung volume reduction surgery. In : Physiologic Basis of Respiratory Disease (Hamid Q, et al, eds) pp744-754. BC Decker Inc, Hamilton, 2005.

30) Chandra D, et al : National Emphysema Treatment Trial Research Group. Perfusion scintigraphy and patient selection for lung volume reduction surgery. Am J Respir Crit Care Med 182 : 937-946, 2010.

31) Weder W, et al : Radiologic emphysema morphology is associated with outcome after surgical lung volume reduction. Ann Thorac Surg 64 : 313-320, 1997.

32) Thurnheer R, et al : Role of lung perfusion scintigraphy in relation to chest computed tomography and pulmonary function in the evaluation of candidates for lung volume reduction surgery. Am J Respir Crit Care Med 158 : 301-310, 1999.

33) Chihara K, et al : Dynamic magnetic resonance imaging-A powerful modality in diagnosis and management of patients with emphysema. In : Mechanics of Breathing, Pathophysiology, Diagnosis, and Treament (Aliverti A, et al, eds) pp60-69. Springer, Milan, 2002.

34) Coxson HO, et al : Selection of patients for lung volume reduction surgery using a power law analysis of the computed tomographic scan. Thorax 58 : 510-514, 2003.

35) Pompeo E, et al : Comparative results of non-resectional lung volume reduction performed by awake or non-awake anesthesia. Eur J Cardiothorac Surg 39 : e51-58, 2011.

36) Decker MR, et al : Lung volume reduction surgery since Nationala Emphysema Treatment Trial : Study od Thoracic Surgeons Databease. J Thorac Cardiovasc Surg 148 : 2651-2658, 2014.

37) Cooper JD, et al : Apples, Poranges, and lemons : Making sense od volume reductiomn surger. J Thorac Cardiovasc Surg 148 : 2470-2471, 2014.

38) van Agteren JEM, et al : Lung volume reduction surgery for diffuse emphysema (review). Cochrane Database Syst Rev 10 : CD001001, 2016.

39) van Agteren JEM, et al : Bronchoscopic Lung volume reduction surgery for chonic obstructive pulmonary disease (review). Cochrane Database Syst Rev 2 : CD012158, 2017.

40) Ingenito E P, et al : Bronchoscopic lung volume reduction using tissue engineering Principles. Am J Respir Crit Care Med 167 : 771-778, 2003.

41) Come CE, et al : A randomised trial of lung sealant versus medical therapy for advanced emphysema. Eur Respir J 46 : 651-662, 2015.

42) Herth FJF, et al : Segmental volume reduction using thermal vapour ablation in patients with severe emphysema : 6 month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respiratory Medicine 4 (3) : 185-193, 2016.

43) Wood DE, et al : The IBV Valve trial : a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol 21 : 288-297, 2014.

44) Ninane V, et al : Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J 39 : 1319-1325, 2012.

45) Davey C, et al : Bronchoscopic lung volume reduction with endobronchial valves for patierlts with heterogeneous emphysema and intact interlobar fissures (the BeLieVeRHIFi study) : a randomised controlled trial. Lancet 386 : 1066-1073, 2015.

46) Valipour A, et al : Endobronchial valve therapy in patients with homogeneous emphysema : results from the IMPACT study. Am J Respir Crit Care Med 194 : 1073-1082, 2016.

47) Koster TD, et al : The fissure : interlobar collateral ventilation and implications for endoscopic therapy in emphysema. Int J Chron Obstruct Pulmon Dis 11 : 765-773, 2016.

48) Klooster K, et al : Endobronchial valves for emphysema without interlobar collateral vennlation. N Engl J Med 373 : 2325-2335, 2015.

49) Bandyopadhyay S, et al : Segmental approach to lung volume reduction therapy for emphysema patients. Respiration 89 (1) : 76-81, 2014.

50) Herth FJF, et al : Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Resp J 39 : 1334-1342, 2012.

51) Argula RG, et al : Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema. Chest 144 : 1578-1586, 2013.

52) Choong CK, et al : Prolongation of patency of airway bypass stents with use of drug-eluting stents. J Thorac Cardiovasc Surg 131 : 60-64, 2006.

53) Shah PL, et al : Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial) : randomised, sham-controlled, multicentre trial. Lancet 378 (9795) : 997-1005, 2011.

54) Macklem PT : Collateral ventilation. N Eng J Med 298 : 49-50, 1978.

P.201 掲載の参考文献

1) Donaldson GC, et al : Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 : 847-852, 2002.

2) Spencer S, et al : Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23 : 698-702, 2004.

3) Connors AF Jr, et al : Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154 : 959-967, 1996.

4) Gunen H, et al : Factors affecting survival of hospitalised patients with COPD. Eur Respir J 26 : 234-241, 2005.

5) Esteban A, et al : Characteristics and outcomes in adult patients receiving mechanical ventilation : a 28-day international study. JAMA 287 : 345-355, 2002.

6) Wouters EF : The burden of COPD in The Netherlands : results from the Confronting COPD survey. Respir Med 97 (Suppl C) : S51-59, 2003.

7) Beasley V, et al : Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis 7 : 555-569, 2012.

8) Soler N, et al : Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157 : 1498-1505, 1998.

9) Sapey E, et al : COPD exacerbations. 2 : aetiology. Thorax 61 : 250-258, 2006.

10) Wedzicha JA, et al : COPD exacerbations : defining their cause and prevention. Lancet 370 : 786-796, 2007.

11) Global Initiative for Chronic Obstructive Lung Disease (GOLD) : GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. 2017. <http://goldcopd.org/gold-2017-global-strategy-diagnosis-managementprevention-copd/>

12) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン 2018. メディカルレビュー社, 東京, 2018.

13) Rodriguez-Roisin R : COPD exacerbations. 5 : management. Thorax 61 (6) : 535-544, 2006.

14) Hurst JR, et al : Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 : 1128-1138, 2010.

15) Celli BR, et al : Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 29 : 1224-1238, 2007.

16) Davies L, et al : Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease : a prospective randomized controlled trial. Lancet 354 : 456-460, 1999.

17) Niewoehner DE, et al : Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340 : 1941-1947, 1999.

18) Thompson WH, et al : Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 154 : 407-412, 1996.

19) Montes de Oca M, et al : ALAT-2014 Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines : questions and answers. Arch Bronconeumol 51 : 403-416, 2015.

20) Leuppi JD, et al : Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease : the REDUCE randomized clinical trial. JAMA 309 : 2223-2231, 2013.

21) Walters JA, et al : Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12 : CD006897, 2014.

22) Vollenweider DJ, et al : Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 12 : CD010257, 2012.

23) Ram FS, et al : Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 19 : CD004403, 2006.

24) Quon BS, et al : Contemporary management of acute exacerbations of COPD : a systematic review and metaanalysis. Chest 133 : 756-766, 2008.

25) Woodhead M, et al : Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26 : 1138-1180, 2005.

26) Kanner RE, et al : Lower respiratory illnesses promote FEV (1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease : results from the lung health study. Am J Respir Crit Care Med 164 : 358-364, 2001.

27) Poole PJ, et al : Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1 : CD002733, 2006.

28) Rodrigo GJ, et al : Tiotropium for the treatment of stable chronic obstructive pulmonary disease : a systematic review with meta-analysis. Pulm Pharmacol Ther 20 : 495-502, 2007.

29) Appleton S, et al : Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3 : CD001104, 2006.

30) Agarwal R, et al : Inhaled corticosteroids vs placebo for preventing COPD exacerbations : a systematic review and metaregression of randomized controlled trials. Chest 137 : 318-325, 2010.

31) Calverley PM, et al : Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 196 : 1219-1221, 2017.

P.210 掲載の参考文献

1) 一般社団法人日本呼吸器学会喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き2018作成委員会編 : 喘息とCOPDのオーバーラップ診断と治療の手引き 2018. メディカルレビュー社, 大阪, 2018.

2) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会監 : 喘息予防・管理ガイドライン 2018 (JGL2018). 協和企画, 東京, 2018.

3) 一般社団法人日本呼吸器学会COPDガイドライン第5版作成委員会編 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版. メディカルレビュー社, 大阪, 2018.

P.217 掲載の参考文献

1) Fletcher C, et al : The natural history of chronic airflow obstruction. Br Med J 1 : 1645-1648, 1977.

2) Kohansal R, et al : The natural history of chronic airflow obstruction revisited : an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 180 (1) : 3-10, 2009.

3) Murray CJ, et al : Evidence-based health policy--lessons from the Global Burden of Disease Study. Science 274 (5288) : 740-743, 1996.

4) Anthonisen NR, et al : The effects of a smoking cessation intervention on 14.5-year mortality : a randomized clinical trial. Ann Intern Med 142 (4) : 233-239, 2005.

5) Mannino DM, et al : Lung function and mortality in the United States : data from the First National Health and Nutrition Examination Survey follow up study. Thorax 58 (5) : 388-393, 2003.

6) Oga T, et al : Analysis of the factors related to mortality in chronic obstructive pulmonary disease : role of exercise capacity and health status. Am J Respir Crit Care Med 167 (4) : 544-549, 2003.

7) Casanova C, et al : Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 (6) : 591-597, 2005.

8) Soler-Cataluna JJ, et al : Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (11) : 925-931, 2005.

9) Waschki B, et al : Physical Activity is the Strongest Predictor of All-Cause Mortality in Patients With COPD : A Prospective Cohort Study. Chest 140 (2) : 331-342, 2011.

10) Celli BR, et al : The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (10) : 1005-1012, 2004.

11) Anthonisen NR, et al : Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 (19) : 1497-1505, 1994.

12) Anthonisen N R, et al : Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 26 (1) : 45-51, 2005.

13) Nichol KL, et al : The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 (12) : 778-784, 1994.

14) Alfageme I, et al : Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61 (3) : 189-195, 2006.

15) Tashkin DP, et al : A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (15) : 1543-1554, 2008.

16) Calverley PM, et al : Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (8) : 775-789, 2007.

17) Vestbo J, et al : Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT) : a double-blind randomised controlled trial. Lancet 387 (10030) : 1817-1826, 2016.

18) Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1 (8222) : 681-686, 1981.

19) Kohnlein T, et al : Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease : a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2 (9) : 698-705, 2014.

20) Marin JM, et al : Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea : the overlap syndrome. Am J Respir Crit Care Med 182 (3) : 325-331, 2010.

P.226 掲載の参考文献

1) Patel JG, et al : Indirect costs in chronic obstructive pulmonary disease : a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis 9 : 289-300, 2014.

2) 五十嵐中, 他 : 【医療経済評価に関する諸問題～理論的・倫理的側面からの検討～】医療経済評価における非関連費用の取扱い. 薬剤疫 17 (1) : 21-26, 2012.

3) Fukuchi Y, et al : COPD in Japan : the Nippon COPD Epidemiology study. Respirology 9 (4) : 458-465, 2004.

4) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD慢性閉塞性肺疾患) 診断と治療のためのガイドライン 2018第5版. メディカルレビュー社, 東京, 2018.

5) 永井厚志, 他 : 日本のCOPDに関する疾病負担の実態 National Health and Wellness Survey (NHWS) より. 呼吸 31 (7) : 659-668, 2012.

6) Miravitlles M, et al : Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121 (5) : 1449-1455, 2002.

7) 西村周三, 他 : 日本におけるCOPD慢性閉塞性肺疾患) 医療費とチオトロピウムの費用対効果. Pharm Med 23 (3) : 165-173, 2005.

8) GOLD日本委員会 : COPD認知度把握調査結果. <http://www.gold-jac.jp/copd_facts_in_japan/copd_degree_of_recognition.html>

9) 厚生科学審議会地域保健健康増進栄養部会次期国民健康づくり運動プラン策定専門委員会 : (健康日本 21 (第2次) の推進に関する参考資料. <http://www.mhlw.go.jp/bunya/kenkou/dl/kenkounippon21_02.pdf>

10) Gershon AS, et al : Health Services Burden of Undiagnosed and Overdiagnosed COPD. Chest 153 : 1336-1346, 2018.

11) Vogelmeier CF, et al : GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. <https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/>

12) 医療経済研究機溝 : 禁煙政策のありかたに関する研究～喫煙によるコスト推計～報告書. <https://www.ihep.jp/publications/report/search.php?y=2010>

13) Igarashi A, et al : Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics 27 (3) : 247-261, 2009.

14) Christenhusz LC, et al : Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine Tob Res 14 (6) : 657-663, 2012.

15) 綾部悦, 他 : 高齢者COPDの急性増悪に対するインフルエンザワクチンの効果. 日呼吸会誌 46 (7) : 511-515, 2008.

16) Heo JY, et al : Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One 12 (5) : e0177342, 2017.

17) 西川正憲 : 高齢者および慢性呼吸器疾患患者における23価肺炎球菌多糖体ワクチンのエビデンスと意義「元気な高齢社会」を支える. 日呼吸ケアリハ会誌 22 (1) : 53-58, 2012.

18) Atsou K, et al : Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France. PLoS One 11 (6) : e0156514, 2016.

19) 石川朗, 他 : COPDへの訪問看護を導入した呼吸リハビリテーションの経済的効果の検討. 日老医会誌 50 (Suppl.) : 95, 2013.

20) Burns DK, et al : The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease : An Economic Evaluation Alongside a Randomised Controlled Trial. Appl Health Econ Health Policy 14 (1) : 105-115, 2016.

21) Price D, et al : Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respir Med 108 (12) : 1786-1793, 2014.

22) Reza Maleki-Yazdi M, et al : Cost Effectiveness of the Long-Acting beta2-Adrenergic Agonist (LABA) /Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/lnhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada France, Italy, and Portugal. Appl Health Econ Health Policy 14 (5) : 579-594, 2016.

23) Tebboth A, et al : UK-specific cost-effectiveness of tiotropium+olodaterol fixed-dose combination versus other LAMA+LABA combinations in patients with COPD. Clinicoecon Outcomes Res 8 : 667-674, 2016.

24) Selya-Hammer C, et al : Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium+olodaterol Respimat (R) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis 10 (5) : 391-401, 2016.

25) Laccase Y, et al : Home Oxygen in Chronic Obstructive Pulmonary Diseases. Am J Respir Crit Care Med 197 (10) : 1254-1264, 2018.

26) Oba Y : Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease. Am J Manag Care 15 (2) : 97-104, 2009.

P.229 掲載の参考文献

1) Fukuchi Y, et al : Respirology 9 (4) : 458, 2004.

2) Osaka D, et al : Intern Med 49 (15) : 1489, 2010.

3) Fukuyama S, et al : Tohoku J Exp Med 238 (2) : 179, 2016.

4) Takiguchi H, et al : PLoS One 13 (5) : e0196132, 2018.

5) Thomsen M, et al : Lancet Respir Med 1 (7) : 543, 2013.

6) Camp PG, et al : Eur Respir J 43 (3) : 725, 2014.

第5章ガイドライン

P.238 掲載の参考文献

1) 日本呼吸器学会COPDガイドライン第5版作成委員会 : COPD慢性閉塞性肺疾患) 診断と治療のためのガイドライン第5版2018. メディカルレビュー社, 大阪, 2018.

2) Fukuchi Y, et al : COPD in Japan : the Nippon COPD Epidemiology study. Respirology 9 : 458-465, 2004.

3) Lange P, et al : Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med 373 : 111-122, 2015.

4) Rabe KF, et al : Chronic obstructive pulmonary disease. Lancet 389 : 1931-1940, 2017.

5) Tsukuya G, et al : Comparison of the COPD Population Screener and International Primary Care Airway Group questionnaires in a general Japanese population : the Hisayama study. Int J Chron Obstruct Pulmon Dis 11 : 1903-1909, 2016.

6) Samukawa T, et al : Development of a self-scored persistent airflow obstruction screening questionnaire in a general Japanese population : the Hisayama study. Int J Chron Obstruct Pulmon Dis 12 : 1469-1481, 2017.

7) 日本呼吸器学会編 : 喘息とCOPDのオーバーラップ (Asthma and COPD Overlap : ACO) 診断と治療の手引き 2018. メディカルレビュー社, 大阪, 2017.

8) 日本呼吸器学会肺生理専門委員会編 : 日本人のスパイログラムと動脈血液ガス分圧共準値. 日呼吸会誌 39 : 巻末14ページ, 2001.

9) GlaxoSmithKline group of companies. COPD Assessment Test 2016. <http://www.catestonlne.org/>

10) Waschki B, et al : Physical activity is the strongest predictor of all-cause mortality in patients with COPD : a prospective cohort study. Chest 140 : 331-342, 2011.

書評

書評を投稿する

最近チェックした商品履歴

Loading...